New drug shows promise for Hard-to-Treat cancers

NCT ID NCT04843709

Completed Disease control Sponsor: Lepu Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called MRG004A in 39 adults with advanced or metastatic solid tumors that have a specific marker called tissue factor. The goal was to find the safest dose and see if the drug can shrink tumors. Researchers monitored side effects and how well the drug worked, but this is an early-stage trial, so more research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Show contact details

Locations

Chao Family Comprehensive Cancer Center

Orange, California, 92868-3201, United States
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 201321, China
Gabrail Cancer Center Research

Canton, Ohio, 44718, United States
Gettysburg Cancer Center

Gettysburg, Pennsylvania, 17325, United States
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Memorial Sloan Kettering 60th Street Outpatient Center

New York, New York, 10065, United States
The Christ Hospital Cancer Center

Cincinnati, Ohio, 45219, United States
The First Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310003, China
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.